Exploring new avenues for modifying course of progression of Alzheimer's disease: The rise of natural medicine

Lye, Sarah; Aust, Caitlin E.; Griffiths, Lyn R.; Fernández, Francisco Sousa

doi:10.1016/j.jns.2021.117332

Cited by 11 publications

(5 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultimately, this would allow insight into how Alzheimer’s could be treated by targeting inflammation in the brain. In addition, certain phytochemical compounds have been shown to reduce the accumulation of amyloid beta and tau protein tangles, and some natural drug candidates are progressing into human clinical trials [ 120 ]. Phytochemical compounds can serve as a good starting point for ligand docking for screening.…”

Section: Discussion: Potential Drug Targets For Regulating Alzheimer’...mentioning

confidence: 99%

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression

Sharo,

Zhai,

Huang

2024

Pharmaceuticals

View full text Add to dashboard Cite

Alzheimer’s disease has become a major public health issue. While extensive research has been conducted in the last few decades, few drugs have been approved by the FDA to treat Alzheimer’s disease. There is still an urgent need for understanding the disease pathogenesis, as well as identifying new drug targets for further drug discovery. Alzheimer’s disease is known to arise from a build-up of amyloid beta (Aβ) plaques as well as tangles of tau proteins. Along similar lines to Alzheimer’s disease, inflammation in the brain is known to stem from the degeneration of tissue and build-up of insoluble materials. A minireview was conducted in this work assessing the genes, proteins, reactions, and pathways that link brain inflammation and Alzheimer’s disease. Existing tools in Systems Biology were implemented to build protein interaction networks, mainly for the classical complement pathway and G protein-coupled receptors (GPCRs), to rank the protein targets according to their interactions. The top 10 protein targets were mainly from the classical complement pathway. With the consideration of existing clinical trials and crystal structures, proteins C5AR1 and GARBG1 were identified as the best targets for further drug discovery, through computational approaches like ligand–protein docking techniques.

show abstract

Section: Discussion: Potential Drug Targets For Regulating Alzheimer’...mentioning

confidence: 99%

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression

Sharo,

Zhai,

Huang

2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Rivastigmine, instead, is a semi-synthetic drug approved by the FDA as a cholinesterase inhibitor recommended for mild-to-moderate AD ( Marucci et al, 2021 ). Based on this promising evidence and on the growing need for natural alternatives with less adverse effects in comparison to pharmaceutical drugs, phytochemical compounds are gaining attention as possible components of preventive or combination therapies aimed at counteracting the AD neurodegeneration ( Jurcau, 2021 ; Lye et al, 2021 ). Many findings have already been provided by the literature about the efficacy of several natural compounds including polyphenols and monoterpenes in affecting different pathogenic mechanisms of AD thanks to their antioxidant and anti-inflammatory properties, and to the ability to modulate the Aβ aggregation and toxicity.…”

Section: Plant-derived Natural Compounds As Multi-target Disease-modi...mentioning

confidence: 99%

Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes

et al. 2022

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a chronic, complex neurodegenerative disorder mainly characterized by the irreversible loss of memory and cognitive functions. Different hypotheses have been proposed thus far to explain the etiology of this devastating disorder, including those centered on the Amyloid-β (Aβ) peptide aggregation, Tau hyperphosphorylation, neuroinflammation and oxidative stress. Nonetheless, the therapeutic strategies conceived thus far to treat AD neurodegeneration have proven unsuccessful, probably due to the use of single-target drugs unable to arrest the progressive deterioration of brain functions. For this reason, the theoretical description of the AD etiology has recently switched from over-emphasizing a single deleterious process to considering AD neurodegeneration as the result of different pathogenic mechanisms and their interplay. Moreover, much relevance has recently been conferred to several comorbidities inducing insulin resistance and brain energy hypometabolism, including diabetes and obesity. As consequence, much interest is currently accorded in AD treatment to a multi-target approach interfering with different pathways at the same time, and to life-style interventions aimed at preventing the modifiable risk-factors strictly associated with aging. In this context, phytochemical compounds are emerging as an enormous source to draw on in the search for multi-target agents completing or assisting the traditional pharmacological medicine. Intriguingly, many plant-derived compounds have proven their efficacy in counteracting several pathogenic processes such as the Aβ aggregation, neuroinflammation, oxidative stress and insulin resistance. Many strategies have also been conceived to overcome the limitations of some promising phytochemicals related to their poor pharmacokinetic profiles, including nanotechnology and synthetic routes. Considering the emerging therapeutic potential of natural medicine, the aim of the present review is therefore to highlight the most promising phytochemical compounds belonging to two major classes, polyphenols and monoterpenes, and to report the main findings about their mechanisms of action relating to the AD pathogenesis.

show abstract

“…Recently, natural medicines, especially Chinese herbal medicines, which act on AD through multiple targets, have been regarded as promising therapeutic approaches ( Zhang C. et al, 2019 ; Lye et al, 2021 ). The blood–brain barrier (BBB) is an important biological barrier between the circulatory and central nervous systems.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles loaded with natural medicines for the treatment of Alzheimer’s disease

Liu,

Ruan,

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that disrupts cognitive function and severely affects the quality of life. Existing drugs only improve cognitive function and provide temporary relief of symptoms but do not stop or delay disease progression. Recently, natural medicines, especially Chinese herbal medicines, have gained attention in the treatment of AD due to their antioxidant, anti-inflammatory, and neuroprotective effects. However, conventional oral dosage forms lack brain specificity and have side effects that lead to poor patient compliance. Utilizing nanomedicine is a promising approach to improve brain specificity, bioavailability, and patient compliance. This review evaluates recent advances in the treatment of AD with nanoparticles containing various natural medicines. This review highlights that nanoparticles containing natural medicines are a promising strategy for the treatment of AD. It is believed that this technology can be translated into the clinic, thereby providing opportunities for AD patients to participate in social activities.

show abstract

Exploring new avenues for modifying course of progression of Alzheimer's disease: The rise of natural medicine

Cited by 11 publications

References 72 publications

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer’s Disease Progression

Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes

Nanoparticles loaded with natural medicines for the treatment of Alzheimer’s disease

Contact Info

Product

Resources

About